Sanofi

Showing 15 posts of 579 posts found.

sanofi_hq__boetie_hall_web

Sanofi’s Dupixent shows strength at Phase 3 in eosinophilic esophagitis

October 27, 2020
Manufacturing and Production Dupixent, Sanofi, pharma

Sanofi has lifted the curtain on new Phase 3 data for Dupixent (dupilumab), showing that the drug met all of …

sanofi_hq__boetie_hall_web

Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis

October 19, 2020
Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis

Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …

nice_new_london_office_internal_3_web

NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma

October 16, 2020
Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …

libtayo

Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma

September 18, 2020
Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …

sanofi_hq__boetie_hall_web

Extension study reveals Dupixent’s benefit can last up to three years in moderate-to-severe asthma

September 8, 2020
Manufacturing and Production, Research and Development Dupixent, Sanofi, asthma, pharma

New findings have been revealed from an extension study of Sanofi’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) in …

800px-sanofi_frankfurt_iph

President of Sanofi France expects COVID-19 vaccine to be priced below ten Euros

September 7, 2020
Sales and Marketing COVID-19, GSK, Sanofi

The President of Sanofi France expects the coronavirus vaccine it is developing with GlaxoSmithKline to be priced under 10 Euros.  …

800px-vaccine

Sanofi halts Phase 3 trial of Kevzara as a COVID-19 treatment

September 1, 2020
Manufacturing and Production COVID-19, Sanofi, Vaccine, pharma

Sanofi is halting clinical trials treating serious COVID-19 patients with its Kevzara drug after data on its efficacy proved inconclusive.The …

6127242068_23c80ef94f_b

Sanofi to buy Principia Biopharma for $3.4 billion

August 17, 2020
Sales and Marketing MS, Sanofi

Sanofi is set to buy California based Principia Biopharma in a deal that is worth $3.4 billion. This deal means …

sanofi_hq

Sanofi indicted on manslaughter charges over its epilepsy drug Depakine

August 4, 2020
Manufacturing and Production Sanofi, Vaccine

Sanofi is being investigated for manslaughter in France over the deaths of four babies whose mothers took its anti-epilepsy medication …

shutterstock_138095450

US Government commits $2.1bn to GSK and Sanofi’s COVID-19 vaccine candidate

July 31, 2020
Medical Communications, Research and Development COVID-19, GSK, Sanofi, US, Vaccine

The US Government has announced additional funding into Sanofi and GlaxSmithKline’s efforts to develop a recombinant protein-based vaccine to the …

Sanofi’s nirsevimab nails study goals for prevention of respiratory syncytial virus in infants

July 30, 2020
Research and Development Sanofi, nirsevimab, pharma

Sanofi’s nirsevimab met its goals in a Phase 2b study, the company has revealed, investigating its efficacy in the prevention …

shutterstock_359806121

UK Government secures 60 million doses of Sanofi and GSK’s COVID-19 vaccine

July 29, 2020
Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK government, pharma

The UK Government has sealed another deal to procure an effective COVID-19 vaccine for its citizens, partnering up with Sanofi …

sanofi

Sanofi’s Dupixent scores Chinese approval in moderate to severe atopic dermatitis

June 22, 2020
Sales and Marketing China, Dupixent, Sanofi, atopic dermatitis, pharma

China’s National Medical Products Administration (NMPA) has moved to approve a 300mg pre-filled pen formulation of Sanofi and Regeneron’s Dupixent …

sanofi

Sanofi drops €610m on new vaccine research and manufacturing sites in France

June 16, 2020
Manufacturing and Production COVID-19, Sanofi

The coronavirus outbreak has changed the way that the world prioritises healthcare resources, and lay bare just how unprepared many …

fda2outsideweb

Mylan and Biocon’s Semglee, biosimilar to Sanofi’s Lantus, approved by FDA for type 1 and 2 diabetes

June 12, 2020
Medical Communications, Sales and Marketing FDA, Lantus, Mylan Biocon, Sanofi, Semglee, diabetes

Mylan and Biocon have scored FDA approval with their insulin glargine injection Semglee, a biosimilar to Sanofi’s Lantus, in both …

The Gateway to Local Adoption Series

Latest content